News
The failure of Roche’s Ionis-partnered tominersen in Huntington’s disease may indicate that Wave Life Sciences’ allele-specific antisense oligonucleotide candidate WVE-003 is on the right track, according to analysts at Rodman & Renshaw.
FEATURED STORIES
The lineup at the Alzheimer’s Association International Conference will provide critical insight into where the industry is headed with regard to targets being explored to vanquish the elusive neurodegenerative disease.
Regulators on both sides of the Atlantic are pushing for the withdrawal of the rare disease treatment that accounted for just 1% of Amgen’s 2025 revenue. Nevertheless, Amgen continues to defend the medicine, which was acquired in the $3.7 billion buyout of ChemoCentryx.
Psychedelics are gaining momentum in depression, with one treating physician predicting that the drug class could “wipe out the SSRIs” if safety and durability hold up.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
Congressional letters sent to the CEOs of Eli Lilly, Pfizer, Merck, BMS and AbbVie this week voicing concerns about the pharmas’ clinical trials in China highlight an ongoing discrepancy in how government and industry think about the rise of the Asian country’s biotech industry.
THE LATEST
This lipid-based system is able to tightly target antigen-presenting cells and thus trigger a rapid, persistent and robust T cell response against various cancers.
The U.S. Food and Drug Administration granted Emergency Use Authorization (EUA) for the Pfizer-BioNTech vaccine for children ages 5 to 11.
Albert Bourla, chief executive officer of Pfizer, argued this week that politicians were approaching the problem of drug pricing the wrong way — as usual.
Daiichi Sankyo announced the decision in its third quarter financial report this morning, where it said that the Phase I data yielded no clear responses in GIST patients.
The 174,000 square-foot location will house a fully-equipped production plant to create its initial programs for Type 1 diabetes, a specific genetic cause of autism, galactosemia, and more.
After first reporting that its investigational RNAi drug vutrisiran hit its 9-month Phase III endpoints, Alnylam announced it continues to demonstrate positive results at the 18-month mark.
In the face of Delta, the actual efficacy of the vaccines has come into question, while global cases and deaths from COVID-19 increased for the first time in two months, primarily in Europe.
Kymera was able to demonstrate for the first time proof-of-biology ex vivo using whole blood from one of their KT-474 treated patient cohorts.
The life sciences industry continues to be one of the fastest growing industries in the world as the end of the year draws near.
Despite these challenges, Raphael remains dedicated to developing the field of cancer metabolism-based therapeutics.